This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview

This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

Precision and Emerging Medicine for Hematological Diseases

Precision and Emerging Medicine for Hematological Diseases

Format

Webcast

Time to Complete

0.50 hours per module (6 total)

Released

March 9, 2018

Expires

March 9, 2019
Add to Queue


Maximum Credits

3.00 / AMA PRA Category 1 CreditsTM  (0.50 credits each [6 modules available])

Accredited Provider

Jointly provided by The Leukemia & Lymphoma Society, RMEI Medical Education, LLC, and Postgraduate Institute for Medicine.

Commercial Supporter

This activity is supported by independent educational grants from AbbVie Inc., Amgen, AstraZeneca Pharmaceuticals LP/Acerta Pharma, and Celgene Corporation. Additional funding provided by The Leukemia & Lymphoma Society.

Program Description

The program will provide the intended audience with cutting edge research about newly approved and emerging treatments for leukemia, lymphoma, and myeloma that can be incorporated into a precision medicine framework to improve outcomes of patients with hematologic malignancies.

Intended Audience

This activity is designed for researchers in hematology/oncology and for hematologists and oncologists who diagnose and treat patients with hematologic malignancies.

Modules Available

Precision Medicine/Technology Overview – Module 1
Karen L. Kaul, MD, PhD

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply new technologies for the detection of molecular abnormalities in hematologic malignancies
  • Identify challenges in education, regulation, and reimbursement for molecular pathology in hematologic malignancies
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.



Clonal Evolution and Targeted Therapies: Deciphering the Future of Myeloma Therapy – Module 2
Jonathan J. Keats, PhD

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss multiple myeloma clonal evolution and how it influences treatment outcomes
  • Identify new developments in myeloma therapy including advances in current therapies, genetic linked treatment, and agents that target pathogenic genetic events through molecular profiling
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.



Precision Medicine in B Cell Lymphoma – Module 3
Sandeep S. Dave, MD, MS

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Describe approaches to genomic applications and functionally evaluating genomic drivers in B cell lymphoma
  • Outline therapeutic opportunities based on a molecular understanding of B cell lymphoma
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.



Precision Medicine in T Cell Lymphoma – Module 4
Wing C. (John) Chan, MD

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the molecular pathogenesis and subtypes of peripheral T cell lymphoma (PTCL)
  • Outline emerging genomic approaches and targeted therapies for PTCL
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.



A New Era in Acute Lymphoblastic Leukemia (ALL): Genomic Analysis of ALL in Children, Adolescents, and Adults from Discovery to Precision Medicine and Targeted Therapeutics – Module 5
Cheryl L. Willman, MD

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Define the current genomic landscape of ALL
  • Discuss important features of a novel form of Ph-like ALL, including deep sequencing, genetic predisposition, clinical trials, and targeted therapeutics
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.



Applying Precision Therapy to Clinical Practice and Panel Discussion and Q&A – Module 6
Anas Younes, MD

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Apply genome sequencing data to select patients for targeted therapy
  • Outline therapeutic strategies to overcome immune tolerance in hematologic malignancies
Credit Available
  • Physicians – maximum of 0.50 AMA PRA Category 1 CreditsTM
All other healthcare professionals completing this course will be issued a statement of participation.

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

Steven T. Rosen, MD, FACP, FASCO, has no affiliations with commercial interests to disclose.

Wing C. (John) Chan, MD, has property rights/patent holder: HealthChart, Nanostring Technologies, Inc.

Sandeep Dave, MD, MS, has no affiliations with commercial interests to disclose.

Karen L. Kaul, MD, PhD, has no affiliations with commercial interests to disclose.

Jonathan J. Keats, PhD, has no affiliations with commercial interests to disclose.

Cheryl L. Willman, MD, has no affiliations with commercial interests to disclose.

Anas Younes, MD, has consulting fees from Bayer, Bristol-Myers Squibb, Celgene Corporation, Genentech, Inc., Incyte, Janssen, Merck, Sanofi, Seattle Genetics, Takeda Millennium and contracted research from Bristol-Myers Squibb, Curis, Inc., Johnson & Johnson, Novartis, Roche.

Accredited Provider Disclosure

Planners and Managers
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.

The Leukemia & Lymphoma Society
Lee Greenberger, PhD, has no affiliations with commercial interests to disclose.
Jim Kasper, MS, has no affiliations with commercial interests to disclose.
Nikay Thomas has no affiliations with commercial interests to disclose.

RMEI Medical Education, LLC
Sherri Kramer, MD, has no affiliations with commercial interests to disclose.
Jessica Hatch has no affiliations with commercial interests to disclose.

Credit

3.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement


In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, The Leukemia & Lymphoma Society, and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credit(s)TM  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(0.50 AMA PRA Category 1 Credit(s)TM  per module)

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Fee Information

There is no fee for this educational activity.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Media Format

Internet

Instructions

HOW TO RECEIVE CREDIT

By reviewing the course content and successfully completing the post-test and evaluation, clinicians are entitled to receive up to 0.50 AMA PRA Category 1 Credit(s)TM  per module (6 modules are available).

To complete these activities, you must register on the CME University website. A copy of your certificate(s) will be saved in your CME University account and will NOT save in your CME History on myCME.

If you have any questions or technical issues, please contact the Postgraduate Institute for Medicine/CME University at information@pimed.com or 303-799-1930.

Add to Queue